18luck新利招商|18新利在线登陆

Skip to content THE SOURCE Close TopicsTopics Arts & Culture Business & Entrepreneurship Campus & Community Humanities & Society Medicine & Health Science & Technology SchoolsSchools Arts & Sciences Brown School McKelvey School of Engineering Olin Business School Sam Fox School of Design & Visual Arts School of Continuing & Professional Studies School of Law School of Medicine PublicationsPublications Newsroom The Record Washington Magazine Search Menu Search for: Search Close NEWSROOM Sections Find an Expert Media Resources Newsroom Stories Perspectives WashU Experts WashU in the News Chemo for glioblastoma enhanced by tapping into cell&＃8217;s daily rhythms Study reveals mechanism for why treatment appears to work better in the morning (Photo: Shutterstock) By Talia Ogliore May 17, 2024 SHARE Glioblastoma is an aggressive brain cancer that has no cure. A recent chart study of patients with glioblastoma found that taking chemotherapy in the morning was associated with a three- to six-month increase in median survival. Now a study from Washington University in St. Louis reports that glioblastoma cells have built-in circadian rhythms that create better times of day for treatment. Gonzalez-Aponte Biologists and clinicians recorded daily rhythms in &＃8220;clock gene&＃8221; expression from a variety of cultured human and mouse glioblastoma cell lines and isolates. These rhythms aligned with daily activity of a DNA repair enzyme known as MGMT. The scientists then conducted tests and found that tumor cells were more likely to die when chemotherapy was administered at the time of day &＃8212; the morning &＃8212; when tumor cells had the least MGMT activity. Repeating their efforts in mice with glioblastoma, the scientists found that morning administration of chemotherapy decreased tumor size and increased body weight compared with evening drug delivery. The study was published in the Journal of Neuro-Oncology. “There might be an avenue for better treating this disease with a drug at the times of day when the cells are more susceptible,” said Maria F. Gonzalez-Aponte, a graduate student in biology in Arts & Sciences at Washington University, who is a first author of the new study. “We found that delivering chemotherapy with temozolomide (TMZ) in the subjective morning can significantly decrease tumor growth and improve disease outcomes for human and mouse models of glioblastoma.” Herzog “Because TMZ is taken orally at home, translation of these findings to patients is relatively simple,” said Erik D. Herzog, PhD, the Viktor Hamburger Distinguished Professor and a professor of biology in Arts & Sciences, corresponding author of the new study. “We will need additional clinical trials to verify our laboratory findings, but evidence so far suggests that the standard-of-care treatment for glioblastoma could be improved simply by asking patients to take the approved drug in the morning,” Herzog said. While largely understudied for TMZ and glioblastoma, the practice of considering time of day in treating disease has been shown to improve outcomes in several cancers, including acute lymphoblastic leukemia, colorectal and ovarian and other gynecological cancers, study authors noted. Joshua B. Rubin, MD, PhD, a professor of pediatrics and of neuroscience at the School of Medicine, is a longtime collaborator with the Herzog laboratory and a co-author on the paper. Gary J. Patti, PhD, a professor of chemistry in Arts & Sciences and of medicine at the School of Medicine, and staff scientist Kevin Cho, PhD, in chemistry are also co-authors. Findings from this study have implications for both treatment and diagnosis of glioblastoma. In general, glioblastoma patients who are diagnosed with what is called MGMT methylated tumors tend to respond better to chemotherapy with TMZ. But this study found that MGMT methylation levels rise and fall based on the circadian time of the tumor. As a result, doctors should control for the time of day when the biopsy of a tumor is taken to properly compare results and improve diagnoses, study authors said. “Despite extensive research over the past 20 years, the median survival for glioblastoma patients post-treatment remains at about 15 months, a grim statistic,” Herzog said. “Incorporating chronotherapy, or timed delivery of drugs, could help improve things.” Herzog, Patti and Rubin are research members of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. Funding: This work was supported by National Institutes of Health (NIH) grants NINDS R21NS120003 and the Washington University Siteman Cancer Center. This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Gonzalez-Aponte, M.F., Damato, A.R., Trebucq, L.L. et al. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. J Neurooncol (2024). https://doi.org/10.1007/s11060-023-04535-9 SHARE Media Contact  Talia Ogliore TopicsBiologyCancer ResearchChemistryScience & Technology Schools Arts & SciencesRead more stories from Arts & SciencesVisit Arts & SciencesSchool of MedicineRead more stories from School of MedicineVisit School of Medicine Leave a Comment Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum. You Might Also Like ‘Fight or flight’ – unless internal clocks are disrupted, study in mice shows October 1, 2021 Published In Newsroom Stories Chemo for glioblastoma may work better in morning than evening March 31, 2021 Published In Newsroom Stories Why do we sleep? Researchers propose an answer to this age-old question January 8, 2024 Published In Newsroom Stories Latest from the Newsroom Recent Stories Reframing voting as ‘duty to others’ key to increasing engagement, turnout Modifying homes for stroke survivors saves lives, extends independence Book explores consequences of political conversations WashU Experts Ten Commandments display probably not legal Social workers key to psychedelic-assisted therapies DeFake tool protects voice recordings from cybercriminals WashU in the News NFL faces ‘Sunday Ticket’ lawsuit: Here’s what’s at stake for the league Transcript: Ezra Klein Interviews Yanna Krupnikov The brain has a waste removal system and scientists are figuring out how it works Publications Washington Magazine Newsroom Record Explore Bookshelf Video Gallery Connect Media Resources Contact Facebook Instagram ©2024 Washington University in St. Louis Go back to top